Research programme: wound healing therapeutics - ADial Pharmaceuticals/University of Virginia
Latest Information Update: 15 Dec 2022
At a glance
- Originator ADial Pharmaceuticals; University of Virginia
- Class Adenine nucleotides; Anti-inflammatories; Small molecules
- Mechanism of Action Adenosine A2A receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Burns
- Research Wounds
Most Recent Events
- 15 Dec 2022 Preclinical trials in Burns in USA (Transdermal), prior to December 2022 (ADial Pharmaceuticals pipeline, December 2022)
- 28 Sep 2021 ADial Pharmaceuticals and University of Virginia agree to co-develop adenosine compounds for wound healing
- 28 Sep 2021 Early research in Wounds in USA (Transdermal)